Currently, there is only one licensed vaccine against tuberculosis (TB), the Bacillus Calmette–
Guérin (BCG). Despite its protective efficacy against TB in children, BCG has failed to protect …

The world is witnessing an escalation of the tuberculosis (TB) epidemic, particularly in sub-
Saharan Africa and South-East Asia. The problem has been compounded by the evolution …

Mycobacterium tuberculosis (M. tb) has co-evolved with humans for thousands of years, to
cause tuberculosis (TB). The success of M. tb as a pathogen is in part because of the ways …

The design of tuberculosis vaccines has entered a new era. Although several new vaccine
candidates will pass Phase I clinical trials within the next year, I believe that the most …

The year 2020 was shaped by the COVID-19 pandemic which killed more people than any
other infectious disease in this particular year. At the same time, the development of highly …

The clinical, social, and economic burden of tuberculosis (TB) remains high worldwide,
thereby highlighting the importance of TB prevention. The bacilli Calmette-Guérin (BCG) …

Substantial efforts have been made over the past decade to develop vaccines against
tuberculosis. We review recent developments in tuberculosis vaccines in the global portfolio …

The past decade has witnessed a tremendous increase in the development of novel
vaccines against tuberculosis (TB). In mice, each of these vaccine candidates stimulates an …

There is a remarkable convergence in the current efforts to develop and evaluate new
tuberculosis (TB) vaccine candidates for use in humans, domestic animals, and wild animal …

The need for a new tuberculosis (TB) vaccination strategy is clear when we consider the
massive burden of TB disease in countries where universal infant bacille Calmette‐Guérin …